TICKERNERD
Menu
NEOGNEOGHealthcare · Medical Devices

NEOG Stock Forecast: Neogen Corp. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$12
+3.41% on the day

The 4 Wall Street analysts covering Neogen Corp. hold a median 12-month price target of $14 — +15.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.6B
Ticker Nerd rank
96 / 100
Median analyst target
$14
Analysts covering
4
Revenue$225.3M−0.1% y/y
Operating income$3.1M
Net income−$11.3M
Free cash flow$26.2M
Quarterly, 8 quarters to 31 May 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.9%
1M
+1.5%
YTD
+73.5%
1Y
+105.2%
From 52W high
−13.2%
From 52W low
+124.2%
$5
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NEOG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neogen Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Growth
84
Value
81
Accruals
79
Revisions
78
Issuance
76
Quality
58
Volatility
53
Size
31

Momentum (94): The shares have been drifting up relative to others.

Volatility (53): The share price moves around a lot.

Size (31): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NEOG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NEOG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26NEOGHigh $14Median $14Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $14Median $14High $14

The green dot is the last close — the median target sits +15.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 Sept 2026GuggenheimMaintainsBuy$12 → $14
26 Aug 2026Piper SandlerUpgradeOverweight$13 → $14
26 Aug 2026Piper SandlerUpgradeOverweight—
3 Aug 2026Piper SandlerReiteratesNeutral$11 → $13
3 Aug 2026Piper SandlerReiteratesNeutral—
12 Jan 2026Piper SandlerReiteratesNeutral—
12 Jan 2026Piper SandlerReiteratesNeutral$6.50 → $10
9 Jan 2026GuggenheimMaintainsBuy—
9 Jan 2026GuggenheimMaintainsBuy$8.00 → $12
10 Dec 2025CJS SecuritiesUpgradeMarket Outperform—
16 Oct 2025Piper SandlerReiteratesNeutral—
29 Sept 2025CJS SecuritiesInitiatesMarket Perform—
29 July 2025William BlairDowngradeMarket Perform—
30 June 2025GuggenheimMaintainsBuy—
22 Apr 2025Piper SandlerMaintainsNeutral—
14 Apr 2025Piper SandlerMaintainsNeutral—
10 Apr 2025GuggenheimMaintainsBuy—
21 Jan 2025Piper SandlerReiteratesNeutral—
19 Dec 2024GuggenheimInitiatesBuy—
6 Aug 2024Piper SandlerMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NEOG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NEOG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Neogen Corp. returned +105.2% against +17.5% for the S&P 500, dividends included.

NEOG vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26NEOGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NEOG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Neogen Corp. (NEOG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
865.0×

Cheaper than 1% of US stocks

Price / sales
2.9×

Cheaper than 41% of US stocks

Price / book
1.2×

Cheaper than 63% of US stocks

EV / EBITDA
29.6×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
6.5%

Higher than 43% of US stocks

Earnings growth (YoY)
−0.1%

Higher than 36% of US stocks

Gross margin
47.8%

Higher than 59% of US stocks

Operating margin
−0.8%

Higher than 31% of US stocks

Net margin
−6.3%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−2.7%

Higher than 42% of US stocks

Return on assets
−0.1%

Higher than 43% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neogen Corp. (NEOG) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neogen Corp. has a market value of $2.6B and an enterprise value of $3.2B.

  • Revenue in the twelve months to 31 May 2026: $870.4M. The latest quarter grew 6.5% year on year.

  • Net income over the same four quarters: −$7.9M, a −0.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.04.

  • Free cash flow in the twelve months to 31 May 2026: $31.9M.

  • Shares outstanding: 217.7M.

  • Trailing P/E: 865.0×; forward P/E: 29.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Neogen Corp. employs 2,636 people — $330K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 May 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

NEOG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NEOGNeogen Corp.$2.6B
96
TMDXTransMedics Group, Inc.$2.6B
34
UFPTUFP Technologies, Inc.$2.2B
81
BFLYButterfly Network, Inc.$2.1B
75
AXGNAxogen, Inc.$2.1B
80
IRTCiRhythm Holdings, Inc.$3.5B
71
INSPInspire Medical Systems, Inc.$1.9B
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neogen Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NEOG news & analysis

Securities Fraud Investigation Into Neogen Corporation (NEOG) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

GlobeNewsWire · 14 Oct 2026negative

The Law Offices of Frank R. Cruz said it is continuing an investigation into Neogen on behalf of investors concerning possible violations of federal securities laws.

Why it matters — The investigation is relevant to NEOG watchers because it concerns potential securities-law issues involving the company and its investors.

3 Medical Product Stocks Positioned to Ride on the Industry Tailwinds

Zacks Investment Research · 9 Oct 2026positive

Zacks highlighted ICUI, NEOG and TRLV as medical product stocks positioned to benefit from industry tailwinds, and said they could be worth adding to investors’ portfolios.

Why it matters — The article presents NEOG as one of three companies it considers well positioned to benefit from industry tailwinds.

Neogen Corporation: Promising Recurring Demand With Food Safety

Seeking Alpha · 8 Oct 2026neutral

The article says Neogen’s recurring food safety products could support its operating recovery, while successful execution of the Petrifilm transition may improve long-term cash flows. It also notes that the genomics sale adds flexibility, though the effect on earnings remains uncertain.

Why it matters — NEOG watchers are monitoring execution of the Petrifilm transition and the earnings impact of the genomics sale.

Neogen Investor Day Sets Path for Growth, 30% EBITDA Margin by 2031

MarketBeat · 8 Oct 2026positive

At its first Investor Day, Neogen outlined a strategy shifting from stabilization toward growth, higher margins and stronger cash generation. Management cited four consecutive quarters of positive core growth and set fiscal 2031 targets including high-single-digit to low-double-digit long-term revenue growth, adjusted EBITDA margins of about 30%, and free-cash-flow conversion of about 80%.

Why it matters — The targets give NEOG watchers a view of management’s long-term growth, profitability and cash-generation objectives.

Neogen Outlines Strategy for Growth, Innovation and Margin Expansion at 2026 Investor Day

Business Wire · 7 Oct 2026positive

Neogen hosted its 2026 Investor Day in New York City, where senior leaders outlined a strategy for sustained profitable growth and category leadership. The company also presented a framework for achieving financial targets by fiscal 2031.

Why it matters — The event gives NEOG watchers an overview of management’s stated growth, innovation and margin-expansion strategy and its long-term financial framework.

FAQ

Frequently asked questions about NEOG stock

What is the NEOG stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Neogen Corp. have a median 12-month price target of $14, with estimates ranging from $14 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NEOG stock a buy right now?

Of the 4 analysts covering Neogen Corp., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neogen Corp. 96 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NEOG?

As at 14 Oct 2026, Neogen Corp. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will NEOG stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +15.4% from the last close, and Ticker Nerd's factor model ranks Neogen Corp. 96 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NEOG stock forecast for 2030?

No analyst covering Neogen Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEOG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $14 over the next 12 months.

How has NEOG stock performed over the past year?

Neogen Corp. returned +105.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neogen Corp. do?

Neogen Corp. is a food and animal safety company that develops, manufactures, and markets diagnostic and testing solutions for regulated industries.

What is the latest news on NEOG?

The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Securities Fraud Investigation Into Neogen Corporation (NEOG) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz". The Law Offices of Frank R. Cruz said it is continuing an investigation into Neogen on behalf of investors concerning possible violations of federal securities laws.

Company

About Neogen Corp.

Neogen Corp. is a food and animal safety company that develops, manufactures, and markets diagnostic and testing solutions for regulated industries. Its Food Safety segment provides test kits, culture media, and related products used by food and feed producers, processors, laboratories, and regulators to detect pathogens, allergens, toxins, drug residues, and sanitation issues. Its Animal Safety segment supplies veterinary instruments, consumables, disinfectants, rodent and insect control products, pharmaceuticals, vaccines, and diagnostic products for veterinarians, livestock producers, and animal health distributors. Neogen Corp. also offers genomics-related services and other products that support animal health and food production workflows. Headquartered in Lansing, Michigan, the company serves customers across food processing, animal protein, agriculture, and companion-animal markets in the United States and internationally.

CEO Mr. Mikhael Nassif · 2,636 employees · United States · https://www.neogen.com